Hydroxylation of desmethylimipramine: dependence on the debrisoquin hydroxylation phenotype.
The 2-hydroxylation of desmethylimipramine (DMI) was studied in 14 healthy subjects previously phenotyped with respect to debrisoquin hydroxylation. After a single oral dose (25 mg), slow hydroxylators of debrisoquin had significantly lower total and metabolic clearances and longer plasma half-lives of DMI and excreted less 2-hydroxydesmethylimipramine than did rapid hydroxylators. These findings strengthen the hypothesis that the hydroxylations of debrisoquin and DMI may be under common enzymatic control.
D000328:Adult; D003647:Debrisoquin / Q000378:metabolism*; D003891:Desipramine / Q000378:metabolism*; D005260:Female; D006207:Half-Life; D006801:Humans; D006900:Hydroxylation; D007546:Isoquinolines / Q000378:metabolism*; D007700:Kinetics; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D010641:Phenotype
D007546:Isoquinolines; D003891:Desipramine; D003647:Debrisoquin